Osteopontin (OPN), TIMP-1, and interleukin (IL)-6 as prognostic (prog) for overall survival (OS) and independent from clinical criteria in patients (pts) with metastatic renal cell carcinoma (mRCC).
Amado J. Zurita
No relevant relationships to disclose
Yuan Liu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Robert C. Gagnon
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Anthony D'Amelio
Employment or Leadership Position - GlaxoSmithKline
Hai T. Tran
No relevant relationships to disclose
Arundathy N. Bartlett-Pandite
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
John Heymach
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline